How have BNR shares performed in 2023?

Burning Rock Biotech's stock was trading at $2.25 at the beginning of the year. Since then, BNR shares have decreased by 60.0% and is now trading at $0.90. View the best growth stocks for 2023 here .

Are investors shorting Burning Rock Biotech?

Burning Rock Biotech saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 476,000 shares, a drop of 7.2% from the October 31st total of 512,700 shares. Based on an average daily trading volume, of 54,200 shares, the days-to-cover ratio is presently 8.8 days. Approximately 0.6% of the company's shares are short sold. View Burning Rock Biotech's Short Interest .

When is Burning Rock Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 30th 2023. View our BNR earnings forecast .

How can I listen to Burning Rock Biotech's earnings call?

Burning Rock Biotech will be holding an earnings conference call on Thursday, November 30th at 7:00 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Burning Rock Biotech's earnings last quarter?

Burning Rock Biotech Limited (NASDAQ:BNR) announced its quarterly earnings data on Thursday, August, 31st. The company reported ($0.18) earnings per share (EPS) for the quarter. The business had revenue of $20.17 million for the quarter. Burning Rock Biotech had a negative net margin of 130.84% and a negative trailing twelve-month return on equity of 68.51%.

What other stocks do shareholders of Burning Rock Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Burning Rock Biotech investors own include Tiziana Life Sciences (TLSA) , Teck Resources (TECK) , Herman Miller (MLHR) and Immunic (IMUX) .

When did Burning Rock Biotech IPO?

(BNR) raised $196 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 13,500,000 shares at a price of $13.50-$15.50 per share. Morgan Stanley, BofA Securities and Cowen served as the underwriters for the IPO and CMBI and Tiger Brokers were co-managers.

Who are Burning Rock Biotech's major shareholders?

Burning Rock Biotech's stock is owned by many different institutional and retail investors. Top institutional investors include Massachusetts Financial Services Co. MA (3.97%), Barclays PLC (0.25%) and Lansdowne Partners UK LLP (0.12%).

How do I buy shares of Burning Rock Biotech?

Shares of BNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Burning Rock Biotech Stock Price, News & Analysis (NASDAQ:BNR)

$0.89

+0.00 (+0.41%)

(As of 02:05 PM ET)

Compare

Today's Range: $0.87
▼
$0.91
50-Day Range: $0.88
▼
$1.13
52-Week Range: $0.87
▼
$3.80

Volume: 29,623 shs
Average Volume: 78,151 shs
Market Capitalization: $91.41 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Burning Rock Biotech MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.56% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.65
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.57) to ($0.25) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Business Services Sector

243rd out of 308 stocks

Medical Laboratories Industry

18th out of 23 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Burning Rock Biotech.

4.0

Short Interest

Percentage of Shares Shorted
0.56% of the float of Burning Rock Biotech has been sold short.
Short Interest Ratio / Days to Cover
Burning Rock Biotech has a short interest ratio ("days to cover") of 8.8.
Change versus previous month
Short interest in Burning Rock Biotech has recently decreased by 7.16%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Burning Rock Biotech does not currently pay a dividend.
Dividend Growth
Burning Rock Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BNR.

2.0

News and Social Media Coverage

News Sentiment
Burning Rock Biotech has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Business Services companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Burning Rock Biotech this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Burning Rock Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
30.30% of the stock of Burning Rock Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 20.83% of the stock of Burning Rock Biotech is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Burning Rock Biotech are expected to grow in the coming year, from ($0.57) to ($0.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Burning Rock Biotech is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Burning Rock Biotech is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Burning Rock Biotech has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Burning Rock Biotech Stock (NASDAQ:BNR)

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

BNR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BNR Stock News Headlines

November 23, 2023 | americanbankingnews.com

Burning Rock Biotech (BNR) Set to Announce Quarterly Earnings on Thursday

November 22, 2023 | finance.yahoo.com

Burning Rock Announces 2023 Annual General Meeting to be Held on December 20, 2023

November 29, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 21, 2023 | finance.yahoo.com

Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023

October 30, 2023 | finanznachrichten.de

Burning Rock Biotech Limited: Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics

October 30, 2023 | finance.yahoo.com

Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics

September 8, 2023 | finance.yahoo.com

Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell

September 1, 2023 | markets.businessinsider.com

Bank of America Securities Keeps Their Buy Rating on Burning Rock Biotech (BNR)

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

September 1, 2023 | finance.yahoo.com

Burning Rock Biotech Limited (NASDAQ:BNR) Q2 2023 Earnings Call Transcript

August 31, 2023 | finance.yahoo.com

Q2 2023 Burning Rock Biotech Ltd Earnings Call

August 31, 2023 | markets.businessinsider.com

Burning Rock Biotech Q2 Loss Narrows

August 31, 2023 | finance.yahoo.com

Burning Rock Reports Second Quarter 2023 Financial Results

August 30, 2023 | markets.businessinsider.com

Burning Rock Biotech is about to announce its earnings — here's what to expect

August 4, 2023 | finance.yahoo.com

Burning Rock Provides Second Quarter 2023 Business Updates and Schedules Earnings Release on August 31, 2023

July 6, 2023 | msn.com

Burning Rock Biotech Ltd - ADR (BNR) Price Target Increased by 15.79% to 6.56

June 28, 2023 | finanznachrichten.de

Burning Rock Biotech Limited: Burning Rock Announces Resignation and Appointment of Directors

June 28, 2023 | finance.yahoo.com

Burning Rock Announces Resignation and Appointment of Directors

June 9, 2023 | finance.yahoo.com

A Look At The Fair Value Of Burning Rock Biotech Limited (NASDAQ:BNR)

June 8, 2023 | benzinga.com

Burning Rock Narrows Losses With Drug Research As New Driver

June 8, 2023 | finance.yahoo.com

Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine

May 31, 2023 | finance.yahoo.com

Burning Rock Biotech Limited (NASDAQ:BNR) Q1 2023 Earnings Call Transcript

May 31, 2023 | finance.yahoo.com

Q1 2023 Burning Rock Biotech Ltd Earnings Call

May 30, 2023 | finance.yahoo.com

Burning Rock Reports First Quarter 2023 Financial Results

May 13, 2023 | finance.yahoo.com

Results: Brenntag SE Exceeded Expectations And The Consensus Has Updated Its Estimates

April 27, 2023 | finance.yahoo.com

Burning Rock Provides First Quarter 2023 Business Updates and Schedules Earnings Release on May 30, 2023

April 20, 2023 | finance.yahoo.com

Burning Rock Publishes 2022 Annual Report on Form 20-F

See More Headlines

Receive BNR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Burning Rock Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/31/2023
Today: 11/29/2023
Next Earnings (Confirmed): 11/30/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Business Services
Current Symbol: NASDAQ:BNR
CUSIP: N/A
CIK: 1792267
Web: www.brbiotech.com
Phone: 86-185-0164-1666
Fax: N/A
Employees: 1,138
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-140,820,000.00
Net Margins: -130.84%
Pretax Margin: -126.22%
Return on Equity: -68.51%
Return on Assets: -50.48%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.09
Quick Ratio: 2.80

Sales & Book Value

Annual Sales: $81.66 million
Price / Sales: 1.11
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.64 per share
Price / Book: 0.54

Miscellaneous

Outstanding Shares: 102,640,000
Free Float: 71,542,000
Market Cap: $91.04 million
Optionable: Not Optionable
Beta: 0.25

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Yusheng Han (Age 44)
Founder, Chairman & CEO
Mr. Jinxiang Li (Age 38)
CFO, Compliance Officer & Director
Dr. Zhihong Zhang (Age 47)
CTO & Director
Mr. Hao Liu (Age 49)
Senior Advisor

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

BNR Stock Analysis - Frequently Asked Questions

How have BNR shares performed in 2023?: Burning Rock Biotech's stock was trading at $2.25 at the beginning of the year. Since then, BNR shares have decreased by 60.0% and is now trading at $0.90.
View the best growth stocks for 2023 here.
Are investors shorting Burning Rock Biotech?: Burning Rock Biotech saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 476,000 shares, a drop of 7.2% from the October 31st total of 512,700 shares. Based on an average daily trading volume, of 54,200 shares, the days-to-cover ratio is presently 8.8 days. Approximately 0.6% of the company's shares are short sold.
View Burning Rock Biotech's Short Interest.
When is Burning Rock Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 30th 2023.
View our BNR earnings forecast.
How can I listen to Burning Rock Biotech's earnings call?: Burning Rock Biotech will be holding an earnings conference call on Thursday, November 30th at 7:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Burning Rock Biotech's earnings last quarter?: Burning Rock Biotech Limited (NASDAQ:BNR) announced its quarterly earnings data on Thursday, August, 31st. The company reported ($0.18) earnings per share (EPS) for the quarter. The business had revenue of $20.17 million for the quarter. Burning Rock Biotech had a negative net margin of 130.84% and a negative trailing twelve-month return on equity of 68.51%.

What other stocks do shareholders of Burning Rock Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Burning Rock Biotech investors own include Tiziana Life Sciences (TLSA), Teck Resources (TECK), Herman Miller (MLHR) and Immunic (IMUX).
When did Burning Rock Biotech IPO?: (BNR) raised $196 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 13,500,000 shares at a price of $13.50-$15.50 per share. Morgan Stanley, BofA Securities and Cowen served as the underwriters for the IPO and CMBI and Tiger Brokers were co-managers.
Who are Burning Rock Biotech's major shareholders?: Burning Rock Biotech's stock is owned by many different institutional and retail investors. Top institutional investors include Massachusetts Financial Services Co. MA (3.97%), Barclays PLC (0.25%) and Lansdowne Partners UK LLP (0.12%).
How do I buy shares of Burning Rock Biotech?: Shares of BNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BNR) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial